Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC)
Compose a Response to This Article
Other responses
No responses have been published for this article.